Dass joins Masood Khan, senior director of immunoanalytical science and technology at the Shawnee, Kansas-based firm. He will assist with the development of GLP-compliant and non-GLP assays for the conduct of large molecule bioanalytical studies, including PK/TK analysis, immunogenicity evaluation and biomarker quantification.
KCAS uses state-of-the-art immunoanalytical technologies to support large molecule bioanalysis for preclinical and clinical studies (Phase I - IV), as well as rapid bioanalysis for biomarker screening pilot projects.
‘We are very fortunate to have both Dr Khan and Dr Dass at KCAS,’ said president and scientific director Dari Dadgar.
‘Their combined knowledge and skill in working with large molecules, specifically LBA services, has positively impacted our capabilities and we look forward to propelled growth and expansion in the future.’
KCAS has recently purchased Meso Scale Discovery’s Sector Imager 6000, an electrochemiluminescence (ECL) detection technology, which will enable the company to offer immunogenicity assays with better drug tolerance and multi-plex panels for biomarker assays.
KCAS expands ligand binding assay team
Proveen Dass joins the company as associate director
You may also like
Manufacturing
RION engages Lonza to scale manufacturing exosome based therapeutics
Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing
Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics
Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials